Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DMX 101

Drug Profile

DMX 101

Alternative Names: APO-200; DMX-101; EDI200; ER-004; Fc EDA1; Fc:EDA-A1 fusion protein; Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein; Hypohidrotic ectodermal dysplasia therapy - Edimer; Recombinant ectodysplasin A1; Recombinant EDA1; XLHED therapy - Edimer

Latest Information Update: 25 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apoxis
  • Developer Dermelix Biotherapeutics; Edimer Pharmaceuticals; EspeRare Foundation
  • Class Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Recombinant fusion proteins; Tumour necrosis factors
  • Mechanism of Action Tumour necrosis factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ectodermal dysplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Clinical Phase Unknown Ectodermal dysplasia

Most Recent Events

  • 02 Apr 2019 EspeRare intends to file PRIME designation for DMX 101 for Ectodermal dysplasia in Europe
  • 02 Apr 2019 Dermelix Biotherapeutics formed a partnership with EspeRare for the development of DMX 101
  • 02 Apr 2019 Preclinical trials in Ectodermal dysplasia in USA (Intra-amniotic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top